Compare Summit Therapeutics Inc (SMMT) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Wheaton Precious Metals Corp — how do they compare? Summit Therapeutics Inc trades at $14.65 (market cap $10.48B), while Wheaton Precious Metals Corp trades at $103.33 (market cap $46.54B). The key difference: Wheaton Precious Metals Corp is far larger — about 4.4× Summit Therapeutics Inc's market cap, and Wheaton Precious Metals Corp pays a 0.75% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | WPM | |
|---|---|---|
Market Cap | $10.48B | $46.54B |
Sector | Health | Basic Materials |
52-Week High | $29.32 | $165.72 |
52-Week Low | $13.05 | $91.00 |
Enterprise Value | $9.90B | $44.39B |
Dividend Yield | — | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting ongoing volatility. The company reported a net loss of $1.08 billion for 2025, with negative ROE and ROA, but recent news includes the $105 million divestiture of ridinilazole to sharpen its oncology focus. Technical indicators are bearish, though RSI suggests potential oversold conditions. Analyst consensus remains optimistic with a $15.57 price target and 66.7% buy ratings.
The outlook hinges on clinical success of its lead oncology candidate, ivonescimab, which showed promising survival data. Key risks include high cash burn, binary drug trial outcomes, and shareholder litigation. The stock offers high-risk, high-reward potential for investors betting on pipeline success, but requires careful risk management due to financial losses and volatility.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
